COVID-19 and Autoimmune/Autoinflammatory Rheumatic Disease Patients: Lessons Learned and Questions Anticipating Answers
Guardado en:
Autores principales: | Athanasios-Dimitrios Bakasis, Haralampos M. Moutsopoulos |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
PCO Convin S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0fb01738b40b44028237ec8d1fe51da3 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents
por: Reimold AM
Publicado: (2012) -
Interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome
por: Pierre Quartier
Publicado: (2011) -
Long-term use of adalimumab in the treatment of rheumatic diseases
por: Charalampos Papagoras, et al.
Publicado: (2009) -
Prevalence of periprosthetic osteolysis after total hip replacement in patients with rheumatic diseases
por: Perez Alamino R, et al.
Publicado: (2012) -
Therapeutic apheresis in autoimmune diseases
por: Bambauer R, et al.
Publicado: (2013)